Navigation Links
Finding about classic suppressor of immunity points toward new therapies for bad infections
Date:1/7/2014

AUGUSTA, Ga. - A well-documented suppressor of immunity that's used by fetuses and tumors alike, just may be able to change its spots, researchers report.

In the face of a significant bacterial infection, for example, indoleomine 2,3-dioxegenase, or IDO, also appears capable of helping key immune cells called macrophages produce inflammation to destroy the invader, said Dr. Tracy L. McGaha, immunologist at the Medical College of Georgia at Georgia Regents University and GRU Cancer Center.

The surprising finding points toward new therapeutic targets when inflammation goes overboard, known as a cytokine storm, as with the overwhelming and highly lethal infection septicemia.

"It's always described as a one-way street, but it appears IDO has a dual role," said McGaha, corresponding author of the study in the journal Molecular and Cellular Biology. "It promotes inflammation when it needs to and, where there is no need for classic inflammation, it can immediately switch to a suppressant mechanism," McGaha said.

IDO's upregulation in macrophages helps these immune cells make important decisions about whether to ignore or attack. "It just depends on the environment the cell finds itself in," McGaha said. He and others also are showing that macrophages, well-documented garbage consumers in the body, have this larger role as well as a driver of the immune response.

While studying more about IDO's role in modulating macrophages response to cell debris, McGaha and his colleagues found that when they added a piece of a bacterial cell wall to prompt an inflammatory reaction, they found an increased number of IDO-expressing macrophages in the mix, which seemed counterintutitive considering IDO's role as a suppressor, McGaha said.

That's how they learned IDO actually does both. IDO basically works by degrading the essential amino acid tryptophan, producing a stress response in the now-starving cell that prompts an increase in the stress response kinase GCN2, which essentially shuts down protein production and cell activity. Unless there is another stressor, which is what happened when the researchers added the bacterial cell wall.

In this infection model, high levels of GCN2 appear instead to nudge macrophages to make more pro-inflammatory mediators, resulting in rampant inflammation in the mice. In this environment, gene activity goes up to the point that the previously sluggish protein production is revived. "The overall affect is you get more inflammation," McGaha said.

And that's where potential new therapies for selectively blocking inflammation surfaced. When they knocked out GCN2, severe inflammation decreased and survival increased in animal models of septicemia. McGaha hopes the laboratory findings will eventually translate to hospital intensive care units.

"Macrophages can do a lot of things and only one of them is make inflammatory products, like cytokines, in response to infection," McGaha said. "They also are involved in wound healing and tissue reconstitution maitenance. So if a macrophage comes into an area that has a lot of mechanical damage, say from trauma, you don't want to make proinflammatory things because that will hurt the ability of the tissue to heal itself."

The good news is that drugs that block GCN2 already are under development to fight cancer and agonists exist that could bolster a positive immune response, such as increasing the potency of a vaccine, McGaha said. "If we can manipulate GCN2's activity in various contexts, we can help finetune the immune response in the direction we want."

Next steps including looking at how GCN2 manipulates immunity, particularly its impact on protein production.

MCG's Drs. Andrew Mellor and David Munn were the first to report that the fetus expresses IDO to help avoid rejection by the mother's immune system. Subsequent studies have shown tumors also use IDO for protection and clinical trials are studying the tumor-fighting potential of an IDO inhibitor. On the flip side, there is evidence that increasing IDO expression can protect transplanted organs and counter autoimmune disease. Mellor and Munn are co-authors on the new study, which was supported in part by the National Institutes of Health and Wellcome Trust.


'/>"/>

Contact: Toni Baker
tbaker@gru.edu
706-721-4421
Medical College of Georgia at Georgia Regents University
Source:Eurekalert  

Related biology news :

1. UMD finding may hold key to Gaia hypothesis
2. ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration
3. Blue Ribbon Panel unveils findings on logistical improvements to support Antarctic science
4. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
5. Team discovers reason that male moths can keep finding females
6. Finding new research frontiers in a single cell
7. New findings on protein misfolding
8. One click away: Finding data on Floridas endangered species just got easier
9. Finding triggers of birth defects in an embryo heart
10. New findings on gene regulation and bone development
11. Verinata Health Announces New Findings At The American Society Of Human Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Finding about classic suppressor of immunity points toward new therapies for bad infections
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):
(Date:6/15/2017)... ... June 15, 2017 , ... ... (EKG) follows an artist’s journey through creative experimentation and interdisciplinary collaboration. Feature Creep, ... through July 22nd. An opening reception will be held at EKG, located at ...
(Date:6/15/2017)... ... June 15, 2017 , ... DuPont Industrial Biosciences (DuPont) ... speaking at Bloomberg’s 2017 Sustainable Business Summit: Seattle this Thursday, June ... officials on a panel titled “Developing a Corporate Renewables Strategy.” , “Consumers ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... 8th to discuss the initiative steered by the executive search firm, “Building Value ... of the Board of Directors of Foundation Medicine, led an open discussion with ...
(Date:6/14/2017)... ... June 14, 2017 , ... ... pumps and process equipment, has appointed Andrew Ondish as Territory Sales Manager for ... a B.S. degree in Petroleum Engineering from Colorado School of Mines. With nearly ...
Breaking Biology Technology: